Commentary

Psychiatric consequences of nitrous oxide abuse


 

References

Identifying N2O use. N2O is not detected on routine drug screen panels. Obtaining a careful psychiatric and substance use history, as well as conducting a neurologic assessment, are helpful to identify N2O use. Both acute and chronic inhalation of N2O can result in vitamin B12 deficiency with hematologic (megaloblastic anemia), neurologic (subacute combined degeneration of spinal cord, motor-sensory polyneuropathy), and psychiatric sequelae (memory loss, depression, hypomania, transient psychosis).1 Patients who exhibit these changes warrant workup for vitamin B12 deficiency, which includes testing for B12, homocysteine, and methylmalonic acid blood levels. Magnetic resonance imaging should be considered for patients who exhibit neurologic symptoms.

The means by which N2O causes neuropsychiatric changes have been explored in the literature. There is general consensus that part of N2O’s deleterious effects is due to the inactivation of vitamin B12 by the irreversible oxidation of Cob(I)alamin to Cob(III)alamin.1

Treatment. The recommended treatment is high-dose oral or parenteral vitamin B12.1 Repletion of vitamin B12 is believed to reverse the course of illness. However, our patient’s symptoms of paranoia and delusions persisted despite resolution of his neurologic symptoms after the underlying vitamin B12 deficiency was corrected.

Due to N2O’s wide availability and growing recreational use, it is important for clinicians to ask their patients about their use of this substance. The abuse of N2O remains an important topic that requires further research, particularly in adolescents, who are still undergoing significant brain development.2,3

Daniel Roberts, MD, MSW
PGY-3 Psychiatric Resident
Department of Psychiatry
New York University Grossman School of Medicine
New York, New York

Pantea Farahmand, MA, MD
Assistant Professor
Department of Psychiatry
New York University Grossman School of Medicine
Inpatient Psychiatrist
Veterans Administration New York Harbor Healthcare System
New York, New York

Adam Wolkin, MD
Associate Professor and Vice Chair
New York University Grossman School of Medicine
Associate Chief of Staff for Mental Health
Veterans Administration New York Harbor Healthcare System
New York, New York

Disclosures: The authors report no financial relationships with any companies whose products are mentioned in this article, or with manufacturers of competing products.

Pages

Recommended Reading

Intense intervention may boost addiction program retention
MDedge Psychiatry
Pharmacotherapy for alcohol use disorder in patients with hepatic impairment
MDedge Psychiatry
Reducing COVID-19 opioid deaths
MDedge Psychiatry
Heavy drinking by teens may affect white-matter integrity
MDedge Psychiatry
Polydoctoring: The case against fragmented psychiatric care
MDedge Psychiatry
Machine learning flags key risk factors for suicide attempts
MDedge Psychiatry
Childhood smoking and depression contribute to young adult opioid use
MDedge Psychiatry
HHS will drop buprenorphine waiver rule for most physicians
MDedge Psychiatry
National spike in methamphetamine overdose deaths
MDedge Psychiatry
Naltrexone cuts hospitalization, deaths in alcohol use disorder
MDedge Psychiatry